497 related articles for article (PubMed ID: 29040782)
1. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
[TBL] [Abstract][Full Text] [Related]
2. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
Kwatra MM
Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of the
Makhlin I; Salinas RD; Zhang D; Jacob F; Ming GL; Song H; Saxena D; Dorsey JF; Nasrallah MP; Morrissette JJ; Binder ZA; O'Rourke DM; Desai AS; Brem S; Bagley SJ
CNS Oncol; 2019 Nov; 8(3):CNS43. PubMed ID: 31769726
[TBL] [Abstract][Full Text] [Related]
4. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
5. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
[TBL] [Abstract][Full Text] [Related]
6. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
Liu F; Mischel PS
Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
8. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
Cho HJ; Zhao J; Jung SW; Ladewig E; Kong DS; Suh YL; Lee Y; Kim D; Ahn SH; Bordyuh M; Kang HJ; Sa JK; Seo YJ; Kim ST; Lim DH; Dho YS; Lee JI; Seol HJ; Choi JW; Park WY; Park CK; Rabadan R; Nam DH
Neuro Oncol; 2019 Jan; 21(1):47-58. PubMed ID: 30085274
[TBL] [Abstract][Full Text] [Related]
9. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
11. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
16. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
17. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathologic diagnosis of epidermal growth factor receptor.
Maire CL; Ligon KL
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii1-6. PubMed ID: 25342599
[TBL] [Abstract][Full Text] [Related]
19. Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
Loriguet L; Morisse MC; Dremaux J; Collet L; Attencourt C; Coutte A; Boone M; Sevestre H; Galmiche A; Gubler B; Chauffert B; Trudel S
BMC Cancer; 2018 Oct; 18(1):964. PubMed ID: 30305059
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report.
Zhou K; Yao H; Zhang X; Liu J; Qi Z; Xie X; Xu X; Zhou Y; Yu Z; Wang Z; Che Y; Huang Y
Oncotarget; 2017 Jul; 8(30):50305-50313. PubMed ID: 28611289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
